29816 Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices

collaborative efforts of it’s program to

(1) assess efficacy of prevention

activities and (2) develop and

implement prevention programs. (15

points)

c. The extent that the applicant

incorporates gathering and using input

from persons with bleeding disorders

and thrombophilia and their family

members, and local consumer and

community based organizations, and the

applicant’s willingness to cooperate

with consumers in the development and

implementation of prevention services.

(5 points)

5. Program management and evaluation

(15 Points)

a. The extent that management

systems, including types, frequency,

and methods of evaluation are used to

ensure appropriate implementation of

program activities. (5 points)

b. The extent of management

experience for recruiting and

implementing large public health

prevention initiatives. (5 points)

c. The degree to which the applicant

has met the CDC Policy requirements

regarding the inclusion of women,

ethnic, and racial groups in the

proposed research. This includes (1) the

proposed plan for the inclusion of both

sexes and racial and ethnic minority

populations for appropriate

representation; (2) the proposed

justification when representation is

limited or absent; (3) a statement as to

whether the design of the study is

adequate to measure differences when

warranted; and (4) a statement as to

whether the plans for recruitment and

outreach for study participants include

the process of establishing partnerships

with community(ies) and recognition of

mutual benefits. (5 points)

6. Budget (Not Scored)

The extent that the budget is

reasonable and consistent with the

intended use of the cooperative

agreement funds.

7. Human Subjects (Not Scored)

Application must adequately address

the requirements of Title 45 CFR Part 46

for the protection of human subjects.

H. Other Requirements

Technical Reporting Requirements

Provide CDC with the original plus

two copies of—

1. Annual progress reports;

2. Financial status report (FSR), no

more than 90 days after the end of the

budget period; and

3. Final financial and performance

reports, no more than 90 days after the

end of the project period.

Send all reports to the Grants

Management Specialist identified in the

‘‘Where to Obtain Additional

Information’’ section of this

announcement.

The following additional

requirements are applicable to this

program. For a complete description of

each, see Attachment I in the

application kit.

AR–1 Human Subjects Requirements

AR–2 Requirements for Inclusion of

Women and Racial and Ethnic

Minorities in Research

AR–10 Smoke-Free Workplace

Requirements

AR–11 Healthy People 2010

AR–12 Lobbying Restrictions

AR–15 Proof of Non-Profit Status

AR–22 Research Integrity

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

section 301(a)[42 U.S.C. 241(a)] and

317(k)(2)[42 U.S.C. 247b9k)(2)] of the

Public Health Service Act, as amended.

The Catalog of Federal Domestic

Assistance number is 93.283.

J. Where To Obtain Additional

Information

This and other CDC announcements

can be found on the CDC home page

Internet address—http://www.cdc.gov

Click on ‘‘Funding’’ then ‘‘Grants and

Cooperative Agreements.’’

To receive additional written

information and to request an

application kit, call 1–888–GRANTS4

(1–888 472–6874). You will be asked to

leave your name and address and will

be instructed to identify the Program

Announcement number of interest.

If you have questions after reviewing

the contents of all the documents,

business management technical

assistance may be obtained from: Merlin

Williams, Grants Management

Specialist, Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention,

2920 Brandywine Road, Room 3000,

MS–K75, Atlanta, GA 30341–4146,

Telephone number: 770–488–2765,

Email: mqw6@cdc.gov.

For program technical assistance,

contact: Sally Crudder, Hemophilia

Treatment Center Program, National

Center for Infectious Diseases, Centers

for Diseases Control and Prevention,

1600 Clifton Road NE, MS–E64, Atlanta,

GA 30333, Telephone Number: 404–

371–5270, Email: sic4@cdc.gov.

Dated: May 25, 2001.

Henry S. Cassell, III,

Acting Director, Procurement and Grants

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 01–13734 Filed 5–31–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 01102]

Cancer Surveillance Research With

Data Enhancement and Utilization,

Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announce the

availability of fiscal year (FY) 2001

funds for a cooperative agreement

program to support priority cancer

surveillance research with data

enhancement and utilization activities.

This program addresses the ‘‘Healthy

People 2010’’ priority areas related to

Cancer.

The purpose of this program is to

utilize data from the National Program

of Cancer Registries (NPCR) to perform

enhanced surveillance and operational

research to include developing,

conducting and evaluating cancer

surveillance research projects targeting

breast, colorectal, prostate, ovarian, and

oral/pharyngeal cancers.

Applicants with interest in innovative

cancer surveillance research activities

are encouraged to apply under this

announcement and, if appropriate, to

partner with universities.

This program consists of 4 parts:

Part I—Breast/Colorectal/Prostate (BCP)

Cancer Patterns of Care (POC),

Recurrence, and Survival (Optional

Breast Cancer Screening Linkage

Component)

The purpose of Part I is to conduct

cancer surveillance research by

comparing detailed clinical information

including stage, diagnostic

investigations used to assess stage

(determinants of stage), and treatment in

large, random samples of patients with

female breast, prostate and colorectal

cancers.

The purpose of the Optional Breast

Cancer Screening Linkage Component is

to validate and assess the completeness

and accuracy of information contained

in the state Breast and Cervical Cancer

Early Detection Program (BCCEDP)

minimum data elements (MDE’s) and to

Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices 29817

sample for comparison of treatment of

early stage breast cancer.

Part II—Reporting Pathology Protocols

(colon and rectum)

The purpose of Part II is to implement

The College of American Pathologists

(CAP) Reporting Protocol for cancers of

the colon and rectum.

Part III—Ovarian Cancer Patterns of

Care

The purpose of Part III is to evaluate

specific information related to the

diagnosis and treatment of ovarian

cancer, including: physician specialty,

accuracy of staging and treatment data,

chemotherapy treatment data, survival

rates, and recurrence.

Part IV—Oral/Pharyngeal Cancer: Data

Completeness and Quality

The purpose of Part IV is to evaluate

the completeness, timeliness and

quality of oral and pharyngeal cancer

and to apply methods to improve data

collection, reliability, and validity.

B. Eligible Applicants

Part I—Eligibility is limited to those

population-based cancer registries

(hereafter referred to as NPCR registries)

listed in Appendix B. Determination of

eligibility is based upon silver or gold

certification by the North American

Association of Central Cancer Registries

(NAACCR) (with the exception of the

timeliness standard) for diagnosis year

1997. This diagnosis year certification is

the most recent available from

NAACCR.

Part II—Eligible applicants are limited

to NPCR registries which can

demonstrate through a letter of support

at least one effective partnership with a

laboratory or laboratory vendor

providing pathologic diagnostic services

in a National Cancer Institute (NCI)

designated comprehensive cancer or

clinical cancer center facility in their

state. Eligible states are listed in

Appendix C.

Part III—Eligibility for Part III is

limited to NPCR registries listed in

Appendix B. Determination of eligibility

is based upon NAACCR silver or gold

certification (with the exception of the

timeliness standard) for diagnosis year

1997.

Part IV—Eligibility for Part IV is

limited to NPCR registries listed in

Appendix B. Determination of eligibility

is based upon NAACCR silver or gold

certification (with the exception of the

timeliness standard) for 1997. Multiple

registries may submit a joint

application.

C. Availability of Funds

Approximately $3,151,000 is available

in FY 2001 to fund the following

categories.

Part I—BCP Cancer Patterns of Care,

Recurrence, and Survival

Approximately $2,056,000 is available

in FY 2001 to fund approximately eight

to ten awards. It is expected that the

average award will be $293,000, ranging

from $260,000 to $325,000.

Part II—Reporting Pathology Protocols

Approximately $300,000 is available

in FY 2001 to fund approximately two

awards. It is expected that the average

award will be $150,000, ranging from

$125,000 to $175,000.

Part III—Ovarian Cancer Patterns of

Care

Approximately $670,000 is available

in FY 2001 to fund approximately three

awards. It is expected that the average

award will be $235,000, ranging from

$200,000 to $270,000.

Part IV—Oral/Pharyngeal Cancer: Data

Completeness and Quality

Approximately $125,000 is available

in FY 2001 to fund up to two awards.

It is expected that the average award

will be $92,000, ranging from $60,000 to

$125,000.

Applicants may apply for one or more

parts depending upon eligibility. It is

expected that awards will begin on or

about September 30, 2001, and will be

made for a 12-month budget period

within a project period of up to three

years. Funding estimates may change.

Continuation awards within an

approved project period will be made

on the basis of satisfactory progress as

evidenced by required reports, research

progress, and the availability of funds.

D. Program Requirements

In conducting activities to achieve the

purposes of Parts I–IV of this program,

the recipient will be responsible for the

activities under 1. (Recipient Activities),

and CDC will be responsible for the

activities listed under 2. (CDC

Activities).

1. Recipient Activities

Recipients for all parts will be

responsible for the following activities:

a. Collaborate with other successful

recipients in part-specific activities.

b. Participate in protocol development

to include the design of the study,

design of the instruments, development

of methods and procedures for the

study, collection of the data, analysis

and interpretation of the data, and

dissemination of results.

c. Assist in the development of a

research protocol for Institutional

Review Board (IRB) review by all

cooperating institutions participating in

the research project. The CDC IRB will

review and approve the protocol

initially and on at least an annual basis

until the research project is completed.

d. Assure and maintain the

confidentiality of all study data.

e. Develop technical reports or

manuscripts for peer-reviewed

publications as appropriate.

Specific activities for each part are as

follows:

Part I

a. Participate in a collaborative North

American/European project between

population-based cancer registries such

as Phase 2 of the Concord Study found

in Appendix G.

b. Participate in additional studies of

patterns of care for cancers of high

public health importance in the U.S.,

including early stage female breast

cancer, stage III colon cancer, and

prostate cancer.

c. Identify appropriate number of

cases as specified in Appendix E.

d. Provide study data to the Data

Analysis Centre, located at the Istituto

Superiore di Sanita in Rome, Italy, with

no direct identifying information, such

as name, address or any public

identification code.

e. Perform joint analysis with data

from other registries and other

countries.

Part I (Option)

a. Conduct a probabilistic linkage

between the state BCCEDP and the state

cancer registry.

b. Resolve potential matched records

identified by the probabilistic linkage.

C. Identify appropriate number of

cases as specified in Appendix E.

d. Collaborate with other successful

recipients of the Part I option in the

resolution of data quality issues and

conduct special analyses relevant to the

linkage of registry and BCCEDP files.

Part II

a. Develop, in collaboration with

other successful recipients, strategies to

implement the CAP reporting protocols

for cancers of the colon and rectum.

b. Develop electronic reporting

capacities to relate data from the

protocols to an appropriate cancer

registry.

c. Implement CAP’s reporting

protocol for cancers of the colon and

rectum.

d. Participate with other successful

applicants and other key groups to share

expertise and experiences.

29818 Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices

e. Provide written feedback and

recommendations regarding the

protocols to improve the protocols for

cancers of the colon and rectum that

will meet the needs of pathologists and

cancer registries.

Part III

a. Identify a minimum of 1,500

ovarian cancer cases diagnosed between

January 1, 1995, and December 31, 1999

within the state.

b. Evaluate medical records to

identify information related to the

diagnosis and treatment of ovarian

cancer, such as: physician specialty,

accuracy of staging and treatment data,

chemotherapy treatment data, survival

rates, and recurrence. chemotherapeutic

drugs provided to the patient.

c. Conduct a linkage between the state

cancer registry file and the state

mortality file to identify deaths that

have occurred among ovarian cancer

patients diagnosed in 1995–1999.

d. Evaluate differences between

cancer stage and treatment data

identified during this study and the

stage of ovarian cancer and cancer

treatment initially reported to the cancer

registry.

Part IV

a. Develop a protocol for auditing

completeness and quality of oral cancer

data, including at a minimum, an

assessment of the quality of the

following variables: stage at diagnosis,

diagnosis year, diagnosis day, date of

birth, race, site, subsite, histology,

grade, sequence, laterality, gender, and

treatment.

b. Determine completeness,

timeliness, and quality of the registry

data on oral and pharyngeal cancers

(defined by ICD–O–2 as C00–C14; ICD–

9 as 140–149; or as defined by other

codes) at several time intervals.

c. Identify any unique problems

associated with reporting and tabulating

data on oral and pharyngeal cancers,

including assessment of source data and

reporting from non-hospital facilities,

such as pathology laboratories, dental

clinics, and oral surgeons.

d. Estimate the number of oral and

pharyngeal cases diagnosed and treated

in non-hospital facilities.

e. Evaluate any deficiencies in

completeness, timeliness, and quality of

oral/pharyngeal cancer data, and the

potential effects of such deficiencies on

the reliability and validity of incidence

and survival estimates. Propose specific

solutions to the deficiencies identified.

f. Evaluate potential strategies for

collapsing data in order to obtain

reliable and stable estimates of

incidence, e.g., by combining data for

anatomical sites or across years.

g. Identify the resources necessary to

maintain completeness, timeliness, and

quality of registry data on oral and

pharyngeal cancer.

h. Serve as the focal point for the

development and dissemination of

media releases, reports and

publications.

2. CDC Activities

CDC will be responsible for the

following activities for all parts:

a. Participate in a post-award meeting

for information sharing, problem

solving, and research protocol

development.

b. Provide ongoing consultation and

technical assistance to successful

recipients.

c. Collaborate in the design of studies,

to include development of sampling

procedures, design of the instruments,

development of methods and

procedures for the studies, collection of

data, analysis and interpretation of data,

resolution of data quality issues and

dissemination of results.

d. Assist in the development of a

research protocol for IRB review by all

cooperating institutions participating in

the research project. The CDC IRB will

review and approve the protocol

initially and on at least an annual basis

until the research project is completed.

e. Obtain an assurance of

confidentiality, clearance from CDC’s

Office of Management and Budget

(OMB), and other clearances as

appropriate.

f. Collaborate to produce technical

reports or manuscripts for peerreviewed publications as appropriate.

E. Content

Letter of Intent (LOI)

A LOI is optional for this program.

However, a non-binding LOI to apply is

requested from potential applicants. The

narrative should be no more than 2,

single-spaced pages, printed on one

side, with one inch margins, and

unreduced font. Your letter should

include the following information:

announcement number, name of the

principal investigator, and specifically

which Parts the applicant plans to apply

for.

Pre-application Conference Call

A pre-application conference call is

scheduled for June 20th at 1:00 p.m.

Eligible applicants are invited to

participate in this conference call. The

purpose of the conference call will be to

communicate the logistics of the

application process and to respond to

any questions applicants may have

regarding this announcement.

Participation in this conference call is

optional. A summary of the questions

and answers will be made available for

those unable to participate. Registration

information for this conference call will

be sent to all eligible applicants by June

15th.

Applications

Use the information in the Program

Requirements, Other Requirements, and

Evaluation Criteria sections for Parts IIV to develop the application content.

Your application will be evaluated on

the criteria listed, so it is important to

follow them in laying out your program

plan. The narrative for each Part should

be no more than 25 double-spaced

pages, printed on one side, with one

inch margins, and unreduced font. The

original and each copy of the

application must be submitted

unstapled and unbound. Pages should

be clearly numbered and a complete

index to the application and any

appendices included.

Applicants may apply for support

under one or more of the four Parts.

Only one application should be

submitted. For each Part include a

separate and complete narrative,

separate budget, and justification that

can stand alone as an application for

review purposes.

Include funding for staff for Parts I, II,

III, and IV to attend (1) a 1-day, postaward meeting in Atlanta; and (2) an

additional 2-day meeting in a city to be

determined later.

The narrative should consist of, at a

minimum, a Plan, Objectives, Methods,

Evaluation and Budget.

F. Submission and Deadline

Letter of Intent (LOI)

On or before June 8, 2001, submit the

LOI to the Grants Management

Specialist identified in the ‘‘Where to

Obtain Additional Information’’ section

of this announcement.

Application

Submit the original and five copies of

PHS–398 (OMB Number 0925–0001)

(adhere to the instructions on the Errata

Instruction Sheet for PHS 398). Forms

are available in the application kit and

at the following Internet address:

http://www.cdc.gov/od/pgo/

forminfo.htm.

On or before July 1, 2001, submit the

application to the Grants Management

Specialist identified in the ‘‘Where to

Obtain Additional Information’’ section

of this announcement.

Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices 29819

Deadline: Applications shall be

considered as meeting the deadline if

they are either:

1. Received on or before the deadline

date; or

2. Sent on or before the deadline date

and received in time for submission to

the independent review group.

(Applicants must request a legibly dated

U.S. Postal Service postmark or obtain

a legibly dated receipt from a

commercial carrier or U.S. Postal

Service. Private metered postmarks shall

not be acceptable as proof of timely

mailing.)

Late: Applications which do not meet

the criteria in 1. or 2. above will be

returned to the applicant.

G. Evaluation Criteria

Each application will be evaluated

individually against the following

criteria by an independent review group

appointed by CDC.

Budget (not scored)

The extent to which the budget is

reasonable, clearly justified, consistent

with the demonstrated need and

proposed activities, and likely to lead to

program success.

Human Subjects (not scored)

Does the application adequately

address the requirements of Title 45

CFR Part 46 for the protection of human

subjects? (Not scored; however, an

application can be disapproved if the

research risks are sufficiently serious

and protection against risks is so

inadequate as to make the entire

application unacceptable.)

Specific evaluation criteria for each

part are as follows:

Part I

1. Program Need (5 points)

a. The extent to which the applicant

demonstrates an effective understanding

of the background of the problem

(variable quality of patterns of care and

validity of stage and treatment data in

the registry), a need for the project, and

a commitment to its execution. (3

points)

b. The degree to which the applicant

has met the CDC Policy requirements

regarding the inclusion of women,

ethnic, and racial groups in the

proposed research. This includes:

(1) The proposed plan for the

inclusion of both sexes (not applicable

for Breast or Prostate sites) and racial

and ethnic minority populations for

appropriate representation.

(2) The proposed justification when

representation is limited or absent.

(3) A statement as to whether the

design of the study is adequate to

measure differences when warranted.

(4) A statement as to whether the

plans for recruitment and outreach for

study participants include the process

of establishing partnerships with

community(ies) and recognition of

mutual benefits. (2 points)

2. Objectives (10 points)

a. The extent to which the applicant

demonstrates that the proposed program

objectives are measurable, specific,

time-phased, and related to the recipient

activities, program purpose, and

program need. (3 points)

b. The extent to which a description

regarding the feasibility of

implementing a North American/

European study protocol such as the

Concord study protocol and U.S. point

of contact activities, including

collecting and reporting data from

medical abstract review and processing

and reporting data to the Concord

Analytic Data Center in Rome, Italy, and

the extent to which feasibility is

demonstrated by the description. (7

points)

3. Methods (40 points)

a. The extent to which the applicant

describes strengths and limitations for

implementing a North American/

European study protocol such as the

Concord study, the U.S. patterns of care

activities, and (optional) breast cancer

screening linkage study. (10 points)

b. The extent to which the applicant

demonstrates sufficient knowledge,

capacity and plans to implement and

coordinate data collection, data

reporting, and data linkage, given the

strengths and limitations described. (20

points)

c. The extent to which the applicant

describes appropriate use of technology

to apply to the collection, linkage and

processing of the data. (5 points)

d. The extent to which plans for

collaborative data analysis and

manuscript preparation are included. (5

points)

4. Evaluation (20 points)

The extent to which the applicant

describes adequate plans for providing

on-going communication including

feedback and quality control suggestions

for improvement and implementation of

study protocols.

5. Program Management and Staffing

Plan (25 points)

The extent to which proposed

staffing, management and organizational

structure, staff background and

experience, job descriptions and

resumes with qualifying experience of

key personnel indicate an ability to

carry out the project.

Part II

1. Program Need (15 points)

a. The extent to which the applicant

demonstrates an effective commitment

and understanding to the project, as

documented through letters of support,

background and need for a standardized

pathology report. (5 points)

b. The extent to which a description

regarding the impact of using

standardized content in the collection

and reporting of pathology data in

general, and specifically for the targeted

cancer sites, colon and rectum, is

provided. (5 points)

c. The extent to which a description

of the need for standardized, electronic

reporting of pathology data for the

targeted cancers to cancer registries is

provided. (5 points)

2. Plan of Operation (45 points)

a. The extent to which a plan is

provided to determine the strengths and

limitations for implementation of the

SNOMED-encoded CAP protocols for

the target sites, for both clinical

purposes and cancer surveillance

purposes. (5 points)

b. The extent to which the applicant

proposes to apply clinical ANSI

standards and others, such as HL7,

SNOMED and Logical Identifiers,

Names, and Codes (LOINC), to the

implementation of the protocols and

subsequent data reporting for

surveillance purposes. (7 points)

c. The extent to which the applicant

provides sufficient knowledge, capacity

and plans to work with clinical ANSI

standards and others, such as HL7,

SNOMED and LOINC. (7 points)

d. The extent to which the applicant

proposes methodologies for

implementation of the protocols, which

are standards-based, flexible, and

portable for other protocols and data

reporting environments. (6 points)

e. The extent to which the applicant

addresses the electronic reporting

challenges, needs, and strategies to

implement the protocol. (6 points)

f. The extent to which the applicant

plans to follow through with the

electronic reporting of the protocol. (5

points)

g. The extent to which the applicant

proposes to use technologies for the

implementation of the protocol. (3

points)

h. The extent to which proposed

technologies are linked with existing

capacities. (4 points)

i. The degree to which the applicant

has met the CDC Policy requirements

29820 Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices

regarding the inclusion of women,

ethnic, and racial groups in the

proposed research. This includes:

(1) The proposed plan for the

inclusion of both sexes and racial and

ethnic minority populations for

appropriate representation.

(2) The proposed justification when

representation is limited or absent.

(3) A statement as to whether the

design of the study is adequate to

measure differences when warranted.

(4) A statement as to whether the

plans for recruitment and outreach for

study participants include the process

of establishing partnerships with

community(ies) and recognition of

mutual benefits. (2 points)

3. Evaluation (20 points)

a. The extent to which the applicant

describes plans providing feedback and

quality control suggestions to the

improvement and implementation of the

protocol for the needs of pathologists

and cancer registries. (10 points)

b. The extent to which the applicant

plans to analyze and document the

impact of the protocol on the collection

and reporting of timely, complete,

accurate, and uniform pathology-related

data. (10 points)

4. Project Management and Staffing Plan

(20 points)

a. The extent to which proposed

staffing, management and organizational

structure, staff background and

experience, job descriptions and

resumes with qualifying experience of

key personnel indicate an ability to

carry out the project. (10 points)

b. The extent to which the applicant

provides appropriate documentation

regarding key partners (including

pathologists and/or registry personnel)

and their involvement in the project. (10

points)

Part III

1. Program Need (5 points)

The extent to which the applicant

demonstrates an effective understanding

of the background of the problem

(variable quality of patterns of care and

validity of stage and treatment data in

the registry), a need for the project, and

a commitment to its execution.

2. Objectives (10 points)

The extent to which the applicant

demonstrates that the proposed program

objectives are measurable, specific,

time-phased, and related to the recipient

activities, program purpose, and

program need.

3. Methods (40 points)

a. The extent to which the applicant

demonstrates sufficient knowledge,

capacity and plans to implement and

coordinate data collection, data

reporting activities, and data linkage,

given the strengths and limitations

described. (20 points)

b. The extent to which the applicant

describes appropriate use of technology

to apply to the collection, linkage and

processing of the data. (10 points)

c. The extent to which plans for

collaborative data analysis and

manuscript preparation are included. (5

points)

d. The degree to which the applicant

has met the CDC Policy requirements

regarding the inclusion of women,

ethnic, and racial groups in the

proposed research. This includes: (5

points)

(1) The proposed plan for the

inclusion of racial and ethnic minority

populations for appropriate

representation.

(2) The proposed justification when

representation is limited or absent.

(3) A statement as to whether the

design of the study is adequate to

measure differences when warranted.

(4) A statement as to whether the

plans for recruitment and outreach for

study participants include the process

of establishing partnerships with

community(ies) and recognition of

mutual benefits.

4. Evaluation (20 points)

The extent to which the applicant

provides an evaluation plan that is

appropriate for measuring progress

toward achieving objectives and

identifying contributing factors when

objectives are not met.

5. Project Management and Staffing Plan

(25 points)

The extent to which proposed

staffing, management and organizational

structure, staff background and

experience, job descriptions and

resumes with qualifying experience of

key personnel indicate an ability to

carry out the project.

Part IV

1. Program Need (15 points)

The extent to which the applicant

demonstrates eligibility as required

under this program announcement,

describes existing strengths and

limitations of the registry, and provides

evidence of access to adequate numbers

of oral and pharyngeal cancer cases by

race and gender to support

accomplishment of the project purpose.

2. Objectives (15 points)

The extent to which the applicant

demonstrates that the proposed program

objectives are measurable, specific,

time-phased, and related to the recipient

activities, program purpose, and

program need.

3. Methods (35 points)

a. The extent to which the applicant

adequately describes (23 points)

(1) The methods that will be used to

accomplish the objectives of the project,

including plans to sample an adequate

number of cases for assessing

completeness and data quality.

(2) Proposed strategies and activities

that are appropriate and feasible to

achieve the project.

b. The extent to which the timetable

incorporates project activities and

milestones and is specific, measurable,

and realistic. (10 points)

c. The degree to which the applicant

has met the CDC Policy requirements

regarding the inclusion of women,

ethnic, and racial groups in the

proposed research. This includes:

(1) The proposed plan for the

inclusion of both sexes and racial and

ethnic minority populations for

appropriate representation.

(2) The proposed justification when

representation is limited or absent.

(3) A statement as to whether the

design of the study is adequate to

measure differences when warranted.

(4) A statement as to whether the

plans for recruitment and outreach for

study participants include the process

of establishing partnerships with

community(ies) and recognition of

mutual benefits. (2 points)

4. Evaluation (15 points)

The extent to which the applicant

provides an evaluation plan that is

appropriate for measuring

accomplishment of project objectives

and identifying contributing factors

when objectives are not met.

5. Project Management and Staffing Plan

(20 points)

The extent to which proposed

staffing, management and organizational

structure, staff background and

experience, job descriptions and

resumes with qualifying experience of

key personnel indicate ability to carry

out the project.

H. Other Requirements

Provide CDC with original plus two

copies of

1. an annual progress report,

addressing progress toward achieving

objectives detailed in the application,

Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices 29821

due 90 days after the end of each budget

period;

2. a financial status report, no more

than 90 days after the end of the budget

period; and

3. a final financial and performance

report, no more than 90 days after the

end of the project period.

Send all reports to the Grants

Management Specialist identified in the

‘‘Where to Obtain Additional

Information’’ section of this

announcement.

The following additional

requirements are applicable to this

program. For a complete description of

each, see Attachment I of the

announcement.

AR–1 Human Subjects Requirements

AR–2 Requirements for Inclusion of

Women and Racial and Ethnic

Minorities in Research

AR–7 Executive Order 12372 Review

AR–8 Public Health System Reporting

Requirements

AR–9 Paperwork Reduction Act

Requirements

AR–10 Smoke-Free Workplace

Requirements

AR–11 Healthy People 2010

AR–12 Lobbying Restrictions

AR–22 Research Integrity

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

section 399H–399L of the Public Health

Service Act, [42 U.S.C. sections 280e–

280e–4; Public Law 102–515], as

amended. The Catalog of Federal

Domestic Assistance number is 93.283.

J. Where To Obtain Additional

Information

This and other CDC announcements

can be found on the CDC home page

Internet address—http://www.cdc.gov.

Click on ‘‘Funding’’ then ‘‘Grants and

Cooperative Agreements.’’

To obtain business management

technical assistance, contact:

Jesse Robertson, Grants Management

Specialist, Grants Management

Branch, Procurement and Grants

Office, Centers for Disease Control

and Prevention, Announcement

01102, 2920 Brandywine Road, Room

3000, MS–E18, Atlanta, GA 30341–

4146, Telephone number: (770) 488–

2747, Email address:

jrobertson@cdc.gov

For program technical assistance,

contact:

Part I

Hannah Weir, PhD, Cancer Surveillance

Branch, Division of Cancer Prevention

and Control, National Center for

Chronic Disease Prevention and

Health Promotion, Centers for Disease

Control and Prevention, 4770 Buford

Hwy., NE, MS–K53, Atlanta, GA

30341–3717, Telephone number:

(770) 488–3006, Email address:

hweir@cdc.gov

Part II

Warren Williams, MPH, Cancer

Surveillance Branch, Division of

Cancer Prevention and Control,

National Center for Chronic Disease

Prevention and Health Promotion,

Centers for Disease Control and

Prevention, 4770 Buford Hwy., NE,

MS–K53, Atlanta, GA 30341–3717,

Telephone number: (770) 488–3095,

Email address: wwilliams1@cdc.gov

Part III

Pamela Logan, MD, MPH, Cancer

Surveillance Branch, Division of Cancer

Prevention and Control, National Center

for Chronic Disease Prevention and

Health Promotion, Centers for Disease

Control and Prevention, 4770 Buford

Hwy., NE, MS–K53, Atlanta, GA 30341–

3717, Telephone number: (770) 488–

4292, Email address: plogan@cdc.gov

Part IV

Claudia Vousden, RN, MPH, Program

Services Branch, Division of Oral

Health, National Center for Chronic

Disease Prevention and Health

Promotion, Centers for Disease

Control and Prevention, 4770 Buford

Hwy., NE, MS–F10, Atlanta, GA

30341–3717, Telephone number:

(770) 488–6056, Email address:

cvousden@cdc.gov

Dated: May 25, 2001.

Henry S. Cassell, III,

Acting Director, Procurement and Grants

Office, Center for Disease Control and

Prevention (CDC).

[FR Doc. 01–13738 Filed 5–31–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICE

Centers for Disease Control and

Prevention

[Program Announcement 01130]

National Program To Promote Physical

Activity Among Youth; Notice of

Availability of Funds Correction

AGENCY: Centers for Disease Control and

Prevention, HHS.

ACTION: Program announcement

number; correction.

SUMMARY: The Centers for Disease

Control and Prevention published

Program Announcement 01030 in the

Federal Register of May 23, 2001, The

Program Announcement number was

incorrect.

FOR FURTHER INFORMATION CONTACT:

Cynthia R. Collins, 770–488–2757

Correction.

In the Federal Register of May 23,

2001, in FR Vol 66, No. 100, Doc. 01–

12984, on page 28518, in the third

column, correct the ‘‘Program

Announcement number’’ caption to

read: [Program Announcement 011230]

as set forth in the heading above.

Dated: May 25, 2001.

Henry S. Cassell III,

Acting Director, Procurement and Grants

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 01–13735 Filed 5–31–01; 8:45 am]

BILLING CODE 4163–18–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 01053]

An Assessment of Respiratory Health

Effects From Exposure to Traffic

Particulate Emissions at a U.S.-Canada

Border Crossing in Western New York;

Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 2001

funds for a grant project for the Buffalo

General Foundation for a project

examining the impact of air pollution on

asthma rates and respiratory illness.

This project addresses the ‘‘Healthy

People 2010’’ focus areas of

Environmental Health and Respiratory

Diseases.

B. Eligible Applicant

Assistance will be provided only to

the Buffalo General Foundation. No

other applications are solicited.

Eligibility is limited to the Buffalo

General Foundation because fiscal year

2001 Federal appropriations specifically

directs CDC to award this foundation

funds to assess the impact of air

pollution on asthma rates and

respiratory illness.

Note: Title 2 of the United States Code,

Chapter 26, section 1611 states that an

organization described in section 501(c)(4) of

the Internal Revenue Code of 1986 that

engages in lobbying activities is not eligible

to receive Federal funds constituting an

award, grant, cooperative agreement,

contract, loan, or any other form.